year 19, Issue 73 (3-2020)
J. Med. Plants 2020, 19(73): 143-151 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rezaei M, Afshari D, Fakhri N. The effect of sodae herbal capsule on migraine headaches. J. Med. Plants 2020; 19 (73) :143-151
URL: http://jmp.ir/article-1-2496-en.html
URL: http://jmp.ir/article-1-2496-en.html
1- Professor of Biostatistics, Biostatistics Department, Social Development and Health Promotion Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
2- Department of Neurology, College of Medicine, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran
3- MSc of Biostatistics Student, Student’s Research Committee, Faculty of Health, Kermanshah University of Medical Sciences, Kermanshah, Iran ,n.fakhri94@yahoo.com
2- Department of Neurology, College of Medicine, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran
3- MSc of Biostatistics Student, Student’s Research Committee, Faculty of Health, Kermanshah University of Medical Sciences, Kermanshah, Iran ,
Abstract: (8069 Views)
Background: Migraine is a common neurobiological disorder and various methods have been proposed for its treatment, including herbal remedies. Sodae is an herbal capsule produced and marketed by “Booali Daroo” Pharmaceutical Company, based on Iran's traditional medicine, in compliance with the instructions of the Food and Drug Administration of Iran and with a license issued by this administration of the Ministry of Health. Objective: The present study was conducted to compare the effects of Sodae and placebo capsules on migraine headaches. Methods: This clinical trial (2017-18) was conducted on 74 migraine patients (based on the International Headache Society definition) in Kermanshah, who was randomly divided into two groups. The intervention and placebo groups received 720 mg Sodae and the Avesil capsules for three months, respectively. Headache characteristics were measured using the Migraine Disability Assessment (MIDAS) and Headache Impact Test-6 (HIT-6). Data were analyzed in SPSS-25 using Mann-Whitney’s and Chi-square tests and the Repeated Measures ANOVA.
Results: The headache characteristics reduced significantly more in the intervention group. Compared to the placebo group, the amount of reduction was higher in the intervention group in the frequency (3.53 ± 0.64 vs. 1.79 ± 0.35;
P = 0.041), the severity (1.81 ± 0.14 vs. 1.10 ± 0.13; P = 0.001) and the duration of attacks (3.05 ± 0.66 vs. 1.35 ± 0.31; P = 0.012). MIDAS and HIT scores were further reduced in the drug group than the placebo group. Nonetheless, no significant differences were observed between the two groups in terms of side-effects (P = 0.486). Conclusion: According to the results, Sodae capsule is significantly more effective than placebo in reducing headache characteristics, and given its limited side-effects, it is recommended for the treatment of migraines.
|
116
|
P = 0.041), the severity (1.81 ± 0.14 vs. 1.10 ± 0.13; P = 0.001) and the duration of attacks (3.05 ± 0.66 vs. 1.35 ± 0.31; P = 0.012). MIDAS and HIT scores were further reduced in the drug group than the placebo group. Nonetheless, no significant differences were observed between the two groups in terms of side-effects (P = 0.486). Conclusion: According to the results, Sodae capsule is significantly more effective than placebo in reducing headache characteristics, and given its limited side-effects, it is recommended for the treatment of migraines.
Type of Study: Research |
Subject:
Traditional Pharmacy & Traditional Medicine
Received: 2019/04/15 | Accepted: 2019/11/3 | Published: 2020/06/6
Received: 2019/04/15 | Accepted: 2019/11/3 | Published: 2020/06/6
References
1. Frewin R and Dowson A. Headache in essential thrombocythaemia. International Journal of Clinical Practice 2012; 66 (10): 976-83. [DOI:10.1111/j.1742-1241.2012.02986.x]
2. Sridevi J, Sriram J and Muthukumar N. Effect of Siddha Medicine Adhimadhuram Sombu Paal Kashayam in the Treatment of Otraithalaivali (Migraine)-A Case Report. Int. J. Rev. Pharmacol. Heal. Res. 2018; 1 (2): 2.
3. Shaik MM, Hassan NB, Tan HL and Gan SH. Quality of life and migraine disability among female migraine patients in a tertiary hospital in Malaysia. BioMed Research International. 2015; 2015: 523717. [DOI:10.1155/2015/523717]
4. Jensen R and Stovner LJ. Epidemiology and comorbidity of headache. The Lancet Neurol. 2008; 7 (4): 354-61. [DOI:10.1016/S1474-4422(08)70062-0]
5. Stovner L, Hagen K, Jensen R, Katsarava Z, Lipton RB, Scher A and et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia. 2007; 27 (3): 193-210. [DOI:10.1111/j.1468-2982.2007.01288.x]
6. Steiner TJ, Stovner LJ, Vos T, Jensen R and Katsarava Z. Migraine is first cause of disability in under 50s: will health politicians now take notice?. J. Headache Pain. 2018; 19: 17. [DOI:10.1186/s10194-018-0846-2]
7. Steiner TJ, Stovner LJ and Vos T. GBD 2015: migraine is the third cause of disability in under 50s. J. Headache Pain. 2016; 17: 104. [DOI:10.1186/s10194-016-0699-5]
8. Sillanpää M and Saarinen MM. Long term outcome of childhood onset headache: A prospective community study. Cephalalgia 2018; 38 (6): 1159-66. [DOI:10.1177/0333102417727536]
9. Scher AI, Wang S-J, Katsarava Z, Buse DC, Fanning KM, Adams AM and et al. Epidemiology of migraine in men: Results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study. Cephalalgia 2019; 39 (2): 296-305. [DOI:10.1177/0333102418786266]
10. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M and et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990 - 2010: a systematic analysis for the Global Burden of Disease Study 2010. The Lancet. 2012; 380 (9859): 2163-96. [DOI:10.1016/S0140-6736(12)61729-2]
11. Farhadi Z, Alidoost S, Behzadifar M, Mohammadibakhsh R, Khodadadi N, Sepehrian R and et al. The prevalence of migraine in Iran: A systematic review and meta-analysis. Iranian Red Crescent Medical Journal. 2016; 18 (10): e40061. [DOI:10.5812/ircmj.40061]
12. Ebnesina H. [Law in Medicine (Persian)], Translated by abdorahman sharafkandi. Tehran: Soroush Publisher; 2010, 58-9 p.
13. Li J-c, Shen X-f, Meng X-l, Zhang Y, Lai X-r. Analgesic effect and mechanism of the three TCM-herbal drug-combination Tou Feng Yu pill on treatment of migraine. Phytomedicine 2011; 18 (8-9): 788-94. [DOI:10.1016/j.phymed.2011.01.008]
14. Palevitch D, Earon G and Carasso R. Feverfew (Tanacetum parthenium) as a prophylactic treatment for migraine: a double‐blind placebo‐controlled study. Phytotherapy Research: An International Journal Devoted to Medical and Scientific Research on Plants and Plant Products 1997; 11 (7): 508-11.
https://doi.org/10.1002/(SICI)1099-1573(199711)11:7<508::AID-PTR153>3.0.CO;2-H [DOI:10.1002/(SICI)1099-1573(199711)11:73.0.CO;2-H]
15. Levin M. Herbal treatment of headache. Headache: The J. Head and Face Pain. 2012; 52: 76-80. [DOI:10.1111/j.1526-4610.2012.02234.x]
16. Benz T, Lehmann S, Gantenbein AR, Sandor PS, Stewart WF, Elfering A and et al. Translation, cross-cultural adaptation and reliability of the German version of the migraine disability assessment (MIDAS) questionnaire. Health Qual Life Outcomes 2018; 16 (1): 42. [DOI:10.1186/s12955-018-0871-5]
17. Zandifar A, Banihashemi M, Haghdoost F, Masjedi SS, Manouchehri N, Asgari F and et al. Reliability and Validity of the Persian HIT‐6 Questionnaire in Migraine and Tension‐type Headache. Pain Practice 2014; 14 (7): 625-31. [DOI:10.1111/papr.12120]
18. Wider B, Pittler MH and Ernst E. Feverfew for preventing migraine. Cochrane Database Syst. Rev. 2015; 4: CD002286. [DOI:10.1002/14651858.CD002286.pub3]
19. Yarnell E. Herbal medicine and migraine. Alternative and Complementary Therapies 2017; 23 (5): 192-201. [DOI:10.1089/act.2017.29131.eya]
20. Maghbooli M, Golipour F, Moghimi A and Yousefi M. Comparison between the efficacy of ginger and sumatriptan in the ablative treatment of the common migraine. Phytother. Res. 2014; 28: 412-5. [DOI:10.1002/ptr.4996]
21. Tan X, Jiao G, Ren Y, Gao X, Ding Y, Wang X and et al. Relationship between smoking and dyslipidemia in western Chinese elderly males. J. Clin. Lab. Anal. 2008; 22 (3): 159-63. [DOI:10.1002/jcla.20235]
22. Nemati. K H, Rakhshandeh H and Esmaeili H. The effect of tanastom partniom in Migraine treatment. (Persian). J. Mashhad University of Medical Sciences 2007; 50 (97): 333-8.
23. Rehman T, Ahmad S and Fatima Q. Effects of dietary supplementations and herbs on migraine-a systematic review. Journal of Complementary and Integrative Medicine. 2019;16 (3). doi: 10.1515/jcim-2018-0143. [DOI:10.1515/jcim-2018-0143]
24. Mohammadtaheri F, Gheysari R and Akhlaghdoost M. the effectiveness of oral peppermint extract on migraine. Anesthesiology and Pain. 2016; 7 (1): 1-12.
25. Shi Y, Wang Y, Fu H, Xu Z, Zeng H and Zheng G. Chinese herbal medicine for headache: A systematic review and meta-analysis of high-quality randomized controlled trials. Phytomedicine: International J. Phytotherapy and Phytopharmacol. 2018; 57: 315. [DOI:10.1016/j.phymed.2018.12.039]
26. Mehta AK and Tripathi CD. Commiphora mukul attenuates peripheral neuropathic pain induced by chronic constriction injury of sciatic nerve in rats. Nutr. Neurosci. 2015; 18 (3): 97-102. [DOI:10.1179/1476830513Y.0000000104]
27. Goyal S, Khilnani G, Singhvi I, Singla S and Khilnani AK. Guggulipid of Commiphora mukul, with antiallodynic and antihyperalgesic activities in both sciatic nerve and spinal nerve ligation models of neuropathic pain. Pharm. Biol. 2013; 51 (12): 1487-98. [DOI:10.3109/13880209.2013.796392]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
